“First-Of-A-Kind” Aerocrine NIOX Nitric Oxide Asthma Test Gets FDA Nod
This article was originally published in The Gray Sheet
Executive Summary
Aerocrine's NIOX asthma monitoring test will allow physicians to closely evaluate the efficacy of asthma therapy in a non-invasive manner, following FDA 510(k) clearance, announced May 1
You may also be interested in...
New Products In Brief
Spiral lead CE mark: Boston Scientific will market its Acuity Spiral left ventricular lead by mid-March outside the United States for use with cardiac resynchronization therapy devices to treat heart failure. The product boasts a 4-French lead tip profile, the smallest tip in the industry, the firm says. Boston Scientific anticipates U.S. approval of the lead by July
New Products In Brief
Spiral lead CE mark: Boston Scientific will market its Acuity Spiral left ventricular lead by mid-March outside the United States for use with cardiac resynchronization therapy devices to treat heart failure. The product boasts a 4-French lead tip profile, the smallest tip in the industry, the firm says. Boston Scientific anticipates U.S. approval of the lead by July
Nitric oxide tests get special controls
Devices are officially downclassified from Class III to Class II in July 7 final rule. A breath nitric oxide test system Class II special controls guidance accompanies the rule. The downclassification was prompted by a petition from Aerocrine AB. The device, which aids in monitoring asthma therapy, received 510(k) clearance earlier this year, following an April 30 classification order (1"The Gray Sheet" May 5, 2003, p. 26)...